Sign in
Taking peoplePhase 2

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

Key facts

Who runs it
R-Pharm International, LLC
Where
Russia14 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
71 people, planned
Started
17 Mar 2023
Expected to end
Jun 2030
Type of study
Interventional, 2 groups
Treatments tested
  • OKZ q4w
Record updated
8 April 2026

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Study informed consent form voluntarily and independently signed by patient legal representative
  • Study assent form voluntarily and independently signed by minor study subject (patient)
  • Male or female patients aged ≥12 and <18 years (cohort 1 - subgroup A) or >2 and <12 years (cohort 1 - subgroup B) or >2 and <18 years (cohort 2) at the time of screening initiation and on Day 0
  • Body weight at the start of screening and on Day 0 ≥45 kg (cohort 1 - subgroup A) or ≥30 and <45 kg (cohort 1 - subgroup B) or ≥18 and <30 kg (cohort 2)
  • A reliable diagnosis of juvenile idiopathic arthritis (JIA) according to the JIA International League of Associations for Rheumatology (ILAR) 1 criteria with onset before the age of 16 years:; Seropositive or seronegative polyarthritis (pJIA) ≥3 months before screening, or; Systemic JIA (sJIA) for ≥3 months before screening, provided that joint symptoms persist without active systemic manifestations for ≥3 months before screening, or; Extended oligoarticular JIA (оJIA) ≥3 months before screening
  • American College of Radiology (ACR) criteria of active polyarthritis are met: 5 or more active joints at screening and on Day 0
  • C-reactive protein (CRP) level on screening or in anamnesis, not associated with alternative causes of increase other than the activity of the underlying disease, ≥6 mg/l
  • Intolerance or failure of methotrexate in the dose of ≥15 mg/m\^2/week (or less, in a case of documented intolerance of higher doses) for ≥3 months in medical history

Who cannot take part

  • Prior use of any drug that acts directly on IL-6 or IL-6R
  • If methotrexate is administered - any change in dose or in a formulation within 6 weeks prior to Day 0
  • Previous therapy with marketed or experimental conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying anti-rheumatic drugs (bDMARDs) within less than 5 elimination half-lives
  • Use of oral steroids in the doses above 0.2 mg/kg or 10 mg/day of prednisolone daily, whatever is lower, or a change in dose within 2 weeks prior to Day 0, or use of parenteral or topical steroids within 4 weeks prior to Day 0
  • Change in dose of a non-steroidal anti-inflammatory drug (NSAID) within ≤2 weeks prior to Day 0
  • Vaccination with live vaccines within 6 weeks before baseline, or planned vaccination with live vaccines during the study and/or within 6 weeks after the last olokizumab administration
  • Active uveitis at screening or uveitis exacerbation within 24 weeks before screening
  • Active course of a disease associated with formation of intestinal diverticula, or any other symptomatic gastrointestinal disease that may increase risk of perforation; or a history of diverticulitis or perforation; or concurrent Crohn's disease or ulcerative colitis
  • Concurrent heart failure New York Heart Association (NYHA) III or IV functional class
  • Exclusion criteria related to concurrent diseases and conditions that may increase potential risk related to participation in the study and study drug exposure
  • Exclusion criteria related to past or current infection other than tuberculosis
  • Suspected or confirmed current tuberculosis (TB) infection, history of an active or latent TB infection
  • Patients with Steinbrocker class IV functional impairment
  • Presence of systemic autoimmune or autoinflammatory disease, except JIA, or chronic autoimmune hepatitis or diseases of the primary immunodeficiencies group
  • Patients with history of macrophage activation syndrome episodes
  • Known hypersensitivity to any component of the study drug
  • Laboratory abnormalities (creatinine ≥1 mg/dL (88 mM) for children aged 12 or ≥1.2 mg/dL (106 mM) for children aged 13 and older; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥1.5 х upper limit normal (ULN); platelets <180,000/mm\^3; white blood count (WBC) <4000/mm\^3; neutrophils <2000/mm\^3; hemoglobin ≤80 g/L
  • In patients with diabetes mellitus - HbA1c > 7% within the last 3 months (non-controlled diabetes mellitus)
  • Pregnant or breast-feeding female participants or planned pregnancy
  • Other protocol-defined non-inclusion criteria apply

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 2 and 17 years old?

This trial is currently available in Russia.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks) depending on patient's weight. Secondary objectives are to evaluate the pharmacodynamic (PD) profile, the long-term efficacy and safety of olokizumab in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years.

The 2 groups in the trial

  • Arm 1: OKZ 64 mg q4wTreatment being tested

    SC injections q4w-Cohort 1

    Treatment: OKZ q4w

  • Arm 2: OKZ 48 mg q4wTreatment being tested

    SC injections q4w-Cohort 2

    Treatment: OKZ q4w

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multicenter Study of the Pharmacokinetics, Efficacy and Safety of Olokizumab in Pediatric and Adolescent Patients With Active Juvenile Idiopathic Arthritis
Criteria questions
Built from NCT07517575, who can take part
Record updated
8 April 2026